A 65-year-old woman who was receiving Eisai’s (ESALY) lecanemab treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a brain hemorrhage that some researchers link to the drug, reported Charles Piller in Science. The clinical trial death, described in an unpublished case report Science has obtained, is "the second thought to be associated with the antibody" and "intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators," according to the report. Shares of Biogen (BIIB), Eisai’s partner on lecanemab, are down $12.18, or 4%, to $292.97 in pre-market trading. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Hedge Fund Point 72 Builds Position in These Stocks; Should You?
- Early notable gainers among liquid option names on November 14th
- Piper still cautious on Biogen but says Roche failure a positive
- Biogen price target raised to $315 from $300 at Oppenheimer
- Biogen Names Christopher Viehbacher President and Chief Executive Officer
